SKU: F044

size  
Quantity:
 
Price: make selection(s)
Description
Fondaprinux is sulfated pentasaccharide , an ultra low molecular weight synthetic form of heparain with antithrombotic properties.  It is analogous to the pentasaccharide sequence in heparin.

    CAS Number

    114870-03-0

    Molecular Formula

    C31H43N3O49S8 · 10Na

    Molecular Weight

    1728.08

    Mechanism of Action

    Fondaprinux Sodium binds antithrombin and inhibits factor Xa. Factor Xa is the activated form of the coagulation factor thrombokinase known as the Stuart-Prower factor.

    Storage Conditions

    -20┬░C

    Tariff Code

    2932.99.9090

Applications

    Eukaryotic Cell Culture Applications

    In vitro, Fondaparinux Sodium was demonstrated to impair thrombin generation in human platelet-poor plasma in a dose-dependent manner. It also inhibited thrombin formation in platelet-rich plasma. Fondaparinux Sodium did not cross-react in vitro with antibodies present in plasma samples associated with heparain-associated thrombocytopenia (Herbert et al, 1997). Monocytes and monocyte-derived microparticles are cell models that play a procoagulant role in acute coronary syndrome by expressing high tissue factor levels, which then trigger thrombin generation. The in-vitro effect of Fondaparinux was compared to Enoxaparin and unfractionated heparin. IC50 values (anti-Xa IU/ml) were 0.59 for activated monocytes and 0.17 for monocyte-derived microparticles (Ben-Hadj-Khalifa et al, 2011).

Specifications

    Form

    Powder

    Appearance

    White to off-white powder

    Source

    Synthetic

References

    References

    Ben-Hadj-Khalifa S (2011) Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul.Fibrinolysis.22(5):369-373 PMID 21577096 Fu L, Suflita M, and Linhardt RJ (2016 Bioengineered heparins and heparan sulfates. Adv. Drug Deliv. Rev. 97:237-249 PMID 26555370 Frank RD (2005) The synthetic pentasaccharide Fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. J.Thromb. Haemost. 2005 3(3):531-540 Herbert M et al (1997) SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc. Drug Rev. 15(1):1-26

Other Items In This Category